Insilico's AI-designed rentosertib shows biological age reversal across six proteomic clocks in Phase IIa
thione · x · 2026-09-15
Insilico Medicine published a Nature Biotechnology study showing its generative-AI-designed IPF drug candidate rentosertib may reverse predicted biological age.
Key points
- First de-novo drug designed with generative AI for an AI-discovered target, evaluated with AI aging clocks
- Using 12-week longitudinal Olink proteomic data from 42 IPF patients, six independently developed proteomic aging clocks (ProtAge, OrganAge, PAC, etc., from Harvard, Oxford, PKU and Insilico) unanimously indicated predicted biological age reversal
- International collaboration spanning Harvard Medical School, Stanford, Broad Institute, RWTH Aachen, Peking University and Westlake University
- Establishes a standardized framework for embedding geroscience endpoints into standard disease trials, aligned with FDA Biomarker/BEST guidelines for dual-purpose aging and disease therapeutics
The same thread also cites Anthropic publishing Claude's computer-checked Lean formalization of Fermat's Last Theorem, completed largely autonomously in 11 days.
More from Research
- FlyWire publishes DIY guide to simulate a fly brain with ~160k neurons — patrickmineault · 2026-09-15
- Stanford and MIT paper: the code harness around an LLM can swing benchmark results up to 6x — burkov · 2026-09-15
- Close to a huge math breakthrough, then scooped by AI: what it means for open science — ScottNover · 2026-09-15
- ECCV 2026 paper ART fixes complex makeup transfer, releases first 2K dataset — jiqizhixin · 2026-09-15
- Why mathematicians resist AI proofs — and why it's not just gatekeeping — rbhar90 · 2026-09-15
- CCN2026 GAC debate recording: is the NeuroAI approach inevitable for understanding the brain? — aran_nayebi · 2026-09-15